EU Clinches Landmark Pharma Reform, but Industry Cites Threat to Competitiveness 12/12/2025 Felix Sassmannshausen Following eleven hours of intense negotiations overnight, the European Union (EU) clinched a landmark agreement on the most significant pharma reform of its medicines market in over 20 years on Thursday. Reached in the final moments of the Danish EU Presidency’s mandate, the deal aims to strike a critical balance stimulating pharma innovation, particularly for […] Continue reading -> No Evidence that Vaccines Cause Autism – New WHO Review Reaffirms 11/12/2025 Elaine Ruth Fletcher A new WHO review has reaffirmed that childhood vaccines don’t cause autism, based on an examination of more than 25 years of studies scoping for possible linkages. There is no causal link, either, between vaccines containing preservatives such as thimerosal or aluminium and autism spectrum disorder (ASD), the review by the Global Advisory Committee on […] Continue reading -> $1.9 Billion in Pledges to Polio Eradication by Gates and Other Donors Narrows Funding Gap 09/12/2025 Editorial team Global leaders pledged US$ 1.9 billion to advance polio eradication on Monday, including a new $1.2 billion commitment by the Gates Foundation. The pledges, made on the margins of Abu Dhabi Finance Week, reduce the remaining budget gap for the Global Polio Eradication Initiative’s (GPEI) to just $440 million through 2029. That’s in comparison by […] Continue reading -> CDC Committee Delays Hepatitis B Vaccine for Newborns in Critical Guidelines Shift 05/12/2025 Sophia Samantaroy A United States vaccine advisory panel, recently reformed to include known vaccine skeptics, voted to eliminate a three-decade-long recommendation that all newborns in the US receive a vaccine to protect against hepatitis B (Hep B) at birth – a change that was denounced immediately by medical groups like the American Academy of Pediatrics and the […] Continue reading -> Gavi Cuts Staff and Support to WHO and UNICEF – Gives More Freedom to Countries to Decide Vaccine Priorities 05/12/2025 Elaine Ruth Fletcher Gavi, the Vaccine Alliance has pared down its staff in its Geneva headquarters, Washington DC and New York by 33% – from 643 to 440 people, the agency confirmed today, following a June replenishment drive that fell about $2 billion short of a $11.9 billion fundraising goal for 2026-2030. Beginning in 2026, the agency will […] Continue reading -> Collaboration Across Africa is Key to Increasing Clinical Trials 05/12/2025 Sophia Samantaroy In Kenya, toxicologists and epidemiologists face a difficult choice: to pursue better-paid work to support their families, or volunteer as reviewers for vaccine clinical trials, often without the compensation needed to cover even their children’s school fees. Their dilemma underscores a broader challenge in Africa’s clinical research ecosystem. Slow, duplicative approval processes and limited regulatory […] Continue reading -> Infection Prevention and Control Falters Post-Pandemic – Increasing AMR Risks 04/12/2025 Elaine Ruth Fletcher The post-pandemic decline in infection-prevention practices, along with the broader crash in global health finance, are undermining progress against antimicrobial resistance – one of the planet’s most urgent health threats. At a recent panel discussion co-hosted by the Geneva Health Forum (GHF), leading experts from WHO, academia, biotech, and patient advocacy warned that national AMR plans […] Continue reading -> WHO Issues First-Ever Guidelines for GLP-1 Drugs – Including Obesity 04/12/2025 Sophia Samantaroy First-ever WHO guidelines recommending the use of glucagon-like peptide-1 (GLP-1) therapies for the treatment of obesity in adults has been issued by the World Health Organization – in what the global health agency said is a “conditional” sign of approval for the cutting edge medications that have become widely popular. The new WHO recommendations go […] Continue reading -> European Commission Moves to Ease AI Rules as WHO Warns of Patient Risks due to Regulatory Vacuum 19/11/2025 Felix Sassmannshausen Technological advances in Artificial Intelligence applications for healthcare are quickly outpacing regulatory and ethical safeguards, creating a dangerous gap in patient safety, warns a milestone report on AI in Health Systems, published Wednesday by the World Health Organization’s European Region (WHO/EURO). Paradoxically, the WHO’s urgent call for tighter AI regulation coincided with a far-reaching European […] Continue reading -> New Malaria Drug Candidate Exceeds Cure Rate for Standard ACTs in Phase 3 Trial 12/11/2025 Felix Sassmannshausen The 97% cure rate for the novel compound, ganaplacide/lumefantrine in a recent Phase 3 trial offers hope for continued progress rolling back malaria even as resistance to artemisinin combination therapies (ACT) escalates. A next-generation antimalarial drug GanLum (ganaplacide/lumefantrine, KLU156) slightly outperformed a standard of care Artemisinin Combination Therapy (ACT) in a recent Phase 3 trial […] Continue reading -> Posts navigation Older posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy
No Evidence that Vaccines Cause Autism – New WHO Review Reaffirms 11/12/2025 Elaine Ruth Fletcher A new WHO review has reaffirmed that childhood vaccines don’t cause autism, based on an examination of more than 25 years of studies scoping for possible linkages. There is no causal link, either, between vaccines containing preservatives such as thimerosal or aluminium and autism spectrum disorder (ASD), the review by the Global Advisory Committee on […] Continue reading -> $1.9 Billion in Pledges to Polio Eradication by Gates and Other Donors Narrows Funding Gap 09/12/2025 Editorial team Global leaders pledged US$ 1.9 billion to advance polio eradication on Monday, including a new $1.2 billion commitment by the Gates Foundation. The pledges, made on the margins of Abu Dhabi Finance Week, reduce the remaining budget gap for the Global Polio Eradication Initiative’s (GPEI) to just $440 million through 2029. That’s in comparison by […] Continue reading -> CDC Committee Delays Hepatitis B Vaccine for Newborns in Critical Guidelines Shift 05/12/2025 Sophia Samantaroy A United States vaccine advisory panel, recently reformed to include known vaccine skeptics, voted to eliminate a three-decade-long recommendation that all newborns in the US receive a vaccine to protect against hepatitis B (Hep B) at birth – a change that was denounced immediately by medical groups like the American Academy of Pediatrics and the […] Continue reading -> Gavi Cuts Staff and Support to WHO and UNICEF – Gives More Freedom to Countries to Decide Vaccine Priorities 05/12/2025 Elaine Ruth Fletcher Gavi, the Vaccine Alliance has pared down its staff in its Geneva headquarters, Washington DC and New York by 33% – from 643 to 440 people, the agency confirmed today, following a June replenishment drive that fell about $2 billion short of a $11.9 billion fundraising goal for 2026-2030. Beginning in 2026, the agency will […] Continue reading -> Collaboration Across Africa is Key to Increasing Clinical Trials 05/12/2025 Sophia Samantaroy In Kenya, toxicologists and epidemiologists face a difficult choice: to pursue better-paid work to support their families, or volunteer as reviewers for vaccine clinical trials, often without the compensation needed to cover even their children’s school fees. Their dilemma underscores a broader challenge in Africa’s clinical research ecosystem. Slow, duplicative approval processes and limited regulatory […] Continue reading -> Infection Prevention and Control Falters Post-Pandemic – Increasing AMR Risks 04/12/2025 Elaine Ruth Fletcher The post-pandemic decline in infection-prevention practices, along with the broader crash in global health finance, are undermining progress against antimicrobial resistance – one of the planet’s most urgent health threats. At a recent panel discussion co-hosted by the Geneva Health Forum (GHF), leading experts from WHO, academia, biotech, and patient advocacy warned that national AMR plans […] Continue reading -> WHO Issues First-Ever Guidelines for GLP-1 Drugs – Including Obesity 04/12/2025 Sophia Samantaroy First-ever WHO guidelines recommending the use of glucagon-like peptide-1 (GLP-1) therapies for the treatment of obesity in adults has been issued by the World Health Organization – in what the global health agency said is a “conditional” sign of approval for the cutting edge medications that have become widely popular. The new WHO recommendations go […] Continue reading -> European Commission Moves to Ease AI Rules as WHO Warns of Patient Risks due to Regulatory Vacuum 19/11/2025 Felix Sassmannshausen Technological advances in Artificial Intelligence applications for healthcare are quickly outpacing regulatory and ethical safeguards, creating a dangerous gap in patient safety, warns a milestone report on AI in Health Systems, published Wednesday by the World Health Organization’s European Region (WHO/EURO). Paradoxically, the WHO’s urgent call for tighter AI regulation coincided with a far-reaching European […] Continue reading -> New Malaria Drug Candidate Exceeds Cure Rate for Standard ACTs in Phase 3 Trial 12/11/2025 Felix Sassmannshausen The 97% cure rate for the novel compound, ganaplacide/lumefantrine in a recent Phase 3 trial offers hope for continued progress rolling back malaria even as resistance to artemisinin combination therapies (ACT) escalates. A next-generation antimalarial drug GanLum (ganaplacide/lumefantrine, KLU156) slightly outperformed a standard of care Artemisinin Combination Therapy (ACT) in a recent Phase 3 trial […] Continue reading -> Posts navigation Older posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy
$1.9 Billion in Pledges to Polio Eradication by Gates and Other Donors Narrows Funding Gap 09/12/2025 Editorial team Global leaders pledged US$ 1.9 billion to advance polio eradication on Monday, including a new $1.2 billion commitment by the Gates Foundation. The pledges, made on the margins of Abu Dhabi Finance Week, reduce the remaining budget gap for the Global Polio Eradication Initiative’s (GPEI) to just $440 million through 2029. That’s in comparison by […] Continue reading -> CDC Committee Delays Hepatitis B Vaccine for Newborns in Critical Guidelines Shift 05/12/2025 Sophia Samantaroy A United States vaccine advisory panel, recently reformed to include known vaccine skeptics, voted to eliminate a three-decade-long recommendation that all newborns in the US receive a vaccine to protect against hepatitis B (Hep B) at birth – a change that was denounced immediately by medical groups like the American Academy of Pediatrics and the […] Continue reading -> Gavi Cuts Staff and Support to WHO and UNICEF – Gives More Freedom to Countries to Decide Vaccine Priorities 05/12/2025 Elaine Ruth Fletcher Gavi, the Vaccine Alliance has pared down its staff in its Geneva headquarters, Washington DC and New York by 33% – from 643 to 440 people, the agency confirmed today, following a June replenishment drive that fell about $2 billion short of a $11.9 billion fundraising goal for 2026-2030. Beginning in 2026, the agency will […] Continue reading -> Collaboration Across Africa is Key to Increasing Clinical Trials 05/12/2025 Sophia Samantaroy In Kenya, toxicologists and epidemiologists face a difficult choice: to pursue better-paid work to support their families, or volunteer as reviewers for vaccine clinical trials, often without the compensation needed to cover even their children’s school fees. Their dilemma underscores a broader challenge in Africa’s clinical research ecosystem. Slow, duplicative approval processes and limited regulatory […] Continue reading -> Infection Prevention and Control Falters Post-Pandemic – Increasing AMR Risks 04/12/2025 Elaine Ruth Fletcher The post-pandemic decline in infection-prevention practices, along with the broader crash in global health finance, are undermining progress against antimicrobial resistance – one of the planet’s most urgent health threats. At a recent panel discussion co-hosted by the Geneva Health Forum (GHF), leading experts from WHO, academia, biotech, and patient advocacy warned that national AMR plans […] Continue reading -> WHO Issues First-Ever Guidelines for GLP-1 Drugs – Including Obesity 04/12/2025 Sophia Samantaroy First-ever WHO guidelines recommending the use of glucagon-like peptide-1 (GLP-1) therapies for the treatment of obesity in adults has been issued by the World Health Organization – in what the global health agency said is a “conditional” sign of approval for the cutting edge medications that have become widely popular. The new WHO recommendations go […] Continue reading -> European Commission Moves to Ease AI Rules as WHO Warns of Patient Risks due to Regulatory Vacuum 19/11/2025 Felix Sassmannshausen Technological advances in Artificial Intelligence applications for healthcare are quickly outpacing regulatory and ethical safeguards, creating a dangerous gap in patient safety, warns a milestone report on AI in Health Systems, published Wednesday by the World Health Organization’s European Region (WHO/EURO). Paradoxically, the WHO’s urgent call for tighter AI regulation coincided with a far-reaching European […] Continue reading -> New Malaria Drug Candidate Exceeds Cure Rate for Standard ACTs in Phase 3 Trial 12/11/2025 Felix Sassmannshausen The 97% cure rate for the novel compound, ganaplacide/lumefantrine in a recent Phase 3 trial offers hope for continued progress rolling back malaria even as resistance to artemisinin combination therapies (ACT) escalates. A next-generation antimalarial drug GanLum (ganaplacide/lumefantrine, KLU156) slightly outperformed a standard of care Artemisinin Combination Therapy (ACT) in a recent Phase 3 trial […] Continue reading -> Posts navigation Older posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy
CDC Committee Delays Hepatitis B Vaccine for Newborns in Critical Guidelines Shift 05/12/2025 Sophia Samantaroy A United States vaccine advisory panel, recently reformed to include known vaccine skeptics, voted to eliminate a three-decade-long recommendation that all newborns in the US receive a vaccine to protect against hepatitis B (Hep B) at birth – a change that was denounced immediately by medical groups like the American Academy of Pediatrics and the […] Continue reading -> Gavi Cuts Staff and Support to WHO and UNICEF – Gives More Freedom to Countries to Decide Vaccine Priorities 05/12/2025 Elaine Ruth Fletcher Gavi, the Vaccine Alliance has pared down its staff in its Geneva headquarters, Washington DC and New York by 33% – from 643 to 440 people, the agency confirmed today, following a June replenishment drive that fell about $2 billion short of a $11.9 billion fundraising goal for 2026-2030. Beginning in 2026, the agency will […] Continue reading -> Collaboration Across Africa is Key to Increasing Clinical Trials 05/12/2025 Sophia Samantaroy In Kenya, toxicologists and epidemiologists face a difficult choice: to pursue better-paid work to support their families, or volunteer as reviewers for vaccine clinical trials, often without the compensation needed to cover even their children’s school fees. Their dilemma underscores a broader challenge in Africa’s clinical research ecosystem. Slow, duplicative approval processes and limited regulatory […] Continue reading -> Infection Prevention and Control Falters Post-Pandemic – Increasing AMR Risks 04/12/2025 Elaine Ruth Fletcher The post-pandemic decline in infection-prevention practices, along with the broader crash in global health finance, are undermining progress against antimicrobial resistance – one of the planet’s most urgent health threats. At a recent panel discussion co-hosted by the Geneva Health Forum (GHF), leading experts from WHO, academia, biotech, and patient advocacy warned that national AMR plans […] Continue reading -> WHO Issues First-Ever Guidelines for GLP-1 Drugs – Including Obesity 04/12/2025 Sophia Samantaroy First-ever WHO guidelines recommending the use of glucagon-like peptide-1 (GLP-1) therapies for the treatment of obesity in adults has been issued by the World Health Organization – in what the global health agency said is a “conditional” sign of approval for the cutting edge medications that have become widely popular. The new WHO recommendations go […] Continue reading -> European Commission Moves to Ease AI Rules as WHO Warns of Patient Risks due to Regulatory Vacuum 19/11/2025 Felix Sassmannshausen Technological advances in Artificial Intelligence applications for healthcare are quickly outpacing regulatory and ethical safeguards, creating a dangerous gap in patient safety, warns a milestone report on AI in Health Systems, published Wednesday by the World Health Organization’s European Region (WHO/EURO). Paradoxically, the WHO’s urgent call for tighter AI regulation coincided with a far-reaching European […] Continue reading -> New Malaria Drug Candidate Exceeds Cure Rate for Standard ACTs in Phase 3 Trial 12/11/2025 Felix Sassmannshausen The 97% cure rate for the novel compound, ganaplacide/lumefantrine in a recent Phase 3 trial offers hope for continued progress rolling back malaria even as resistance to artemisinin combination therapies (ACT) escalates. A next-generation antimalarial drug GanLum (ganaplacide/lumefantrine, KLU156) slightly outperformed a standard of care Artemisinin Combination Therapy (ACT) in a recent Phase 3 trial […] Continue reading -> Posts navigation Older posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy
Gavi Cuts Staff and Support to WHO and UNICEF – Gives More Freedom to Countries to Decide Vaccine Priorities 05/12/2025 Elaine Ruth Fletcher Gavi, the Vaccine Alliance has pared down its staff in its Geneva headquarters, Washington DC and New York by 33% – from 643 to 440 people, the agency confirmed today, following a June replenishment drive that fell about $2 billion short of a $11.9 billion fundraising goal for 2026-2030. Beginning in 2026, the agency will […] Continue reading -> Collaboration Across Africa is Key to Increasing Clinical Trials 05/12/2025 Sophia Samantaroy In Kenya, toxicologists and epidemiologists face a difficult choice: to pursue better-paid work to support their families, or volunteer as reviewers for vaccine clinical trials, often without the compensation needed to cover even their children’s school fees. Their dilemma underscores a broader challenge in Africa’s clinical research ecosystem. Slow, duplicative approval processes and limited regulatory […] Continue reading -> Infection Prevention and Control Falters Post-Pandemic – Increasing AMR Risks 04/12/2025 Elaine Ruth Fletcher The post-pandemic decline in infection-prevention practices, along with the broader crash in global health finance, are undermining progress against antimicrobial resistance – one of the planet’s most urgent health threats. At a recent panel discussion co-hosted by the Geneva Health Forum (GHF), leading experts from WHO, academia, biotech, and patient advocacy warned that national AMR plans […] Continue reading -> WHO Issues First-Ever Guidelines for GLP-1 Drugs – Including Obesity 04/12/2025 Sophia Samantaroy First-ever WHO guidelines recommending the use of glucagon-like peptide-1 (GLP-1) therapies for the treatment of obesity in adults has been issued by the World Health Organization – in what the global health agency said is a “conditional” sign of approval for the cutting edge medications that have become widely popular. The new WHO recommendations go […] Continue reading -> European Commission Moves to Ease AI Rules as WHO Warns of Patient Risks due to Regulatory Vacuum 19/11/2025 Felix Sassmannshausen Technological advances in Artificial Intelligence applications for healthcare are quickly outpacing regulatory and ethical safeguards, creating a dangerous gap in patient safety, warns a milestone report on AI in Health Systems, published Wednesday by the World Health Organization’s European Region (WHO/EURO). Paradoxically, the WHO’s urgent call for tighter AI regulation coincided with a far-reaching European […] Continue reading -> New Malaria Drug Candidate Exceeds Cure Rate for Standard ACTs in Phase 3 Trial 12/11/2025 Felix Sassmannshausen The 97% cure rate for the novel compound, ganaplacide/lumefantrine in a recent Phase 3 trial offers hope for continued progress rolling back malaria even as resistance to artemisinin combination therapies (ACT) escalates. A next-generation antimalarial drug GanLum (ganaplacide/lumefantrine, KLU156) slightly outperformed a standard of care Artemisinin Combination Therapy (ACT) in a recent Phase 3 trial […] Continue reading -> Posts navigation Older posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy
Collaboration Across Africa is Key to Increasing Clinical Trials 05/12/2025 Sophia Samantaroy In Kenya, toxicologists and epidemiologists face a difficult choice: to pursue better-paid work to support their families, or volunteer as reviewers for vaccine clinical trials, often without the compensation needed to cover even their children’s school fees. Their dilemma underscores a broader challenge in Africa’s clinical research ecosystem. Slow, duplicative approval processes and limited regulatory […] Continue reading -> Infection Prevention and Control Falters Post-Pandemic – Increasing AMR Risks 04/12/2025 Elaine Ruth Fletcher The post-pandemic decline in infection-prevention practices, along with the broader crash in global health finance, are undermining progress against antimicrobial resistance – one of the planet’s most urgent health threats. At a recent panel discussion co-hosted by the Geneva Health Forum (GHF), leading experts from WHO, academia, biotech, and patient advocacy warned that national AMR plans […] Continue reading -> WHO Issues First-Ever Guidelines for GLP-1 Drugs – Including Obesity 04/12/2025 Sophia Samantaroy First-ever WHO guidelines recommending the use of glucagon-like peptide-1 (GLP-1) therapies for the treatment of obesity in adults has been issued by the World Health Organization – in what the global health agency said is a “conditional” sign of approval for the cutting edge medications that have become widely popular. The new WHO recommendations go […] Continue reading -> European Commission Moves to Ease AI Rules as WHO Warns of Patient Risks due to Regulatory Vacuum 19/11/2025 Felix Sassmannshausen Technological advances in Artificial Intelligence applications for healthcare are quickly outpacing regulatory and ethical safeguards, creating a dangerous gap in patient safety, warns a milestone report on AI in Health Systems, published Wednesday by the World Health Organization’s European Region (WHO/EURO). Paradoxically, the WHO’s urgent call for tighter AI regulation coincided with a far-reaching European […] Continue reading -> New Malaria Drug Candidate Exceeds Cure Rate for Standard ACTs in Phase 3 Trial 12/11/2025 Felix Sassmannshausen The 97% cure rate for the novel compound, ganaplacide/lumefantrine in a recent Phase 3 trial offers hope for continued progress rolling back malaria even as resistance to artemisinin combination therapies (ACT) escalates. A next-generation antimalarial drug GanLum (ganaplacide/lumefantrine, KLU156) slightly outperformed a standard of care Artemisinin Combination Therapy (ACT) in a recent Phase 3 trial […] Continue reading -> Posts navigation Older posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy
Infection Prevention and Control Falters Post-Pandemic – Increasing AMR Risks 04/12/2025 Elaine Ruth Fletcher The post-pandemic decline in infection-prevention practices, along with the broader crash in global health finance, are undermining progress against antimicrobial resistance – one of the planet’s most urgent health threats. At a recent panel discussion co-hosted by the Geneva Health Forum (GHF), leading experts from WHO, academia, biotech, and patient advocacy warned that national AMR plans […] Continue reading -> WHO Issues First-Ever Guidelines for GLP-1 Drugs – Including Obesity 04/12/2025 Sophia Samantaroy First-ever WHO guidelines recommending the use of glucagon-like peptide-1 (GLP-1) therapies for the treatment of obesity in adults has been issued by the World Health Organization – in what the global health agency said is a “conditional” sign of approval for the cutting edge medications that have become widely popular. The new WHO recommendations go […] Continue reading -> European Commission Moves to Ease AI Rules as WHO Warns of Patient Risks due to Regulatory Vacuum 19/11/2025 Felix Sassmannshausen Technological advances in Artificial Intelligence applications for healthcare are quickly outpacing regulatory and ethical safeguards, creating a dangerous gap in patient safety, warns a milestone report on AI in Health Systems, published Wednesday by the World Health Organization’s European Region (WHO/EURO). Paradoxically, the WHO’s urgent call for tighter AI regulation coincided with a far-reaching European […] Continue reading -> New Malaria Drug Candidate Exceeds Cure Rate for Standard ACTs in Phase 3 Trial 12/11/2025 Felix Sassmannshausen The 97% cure rate for the novel compound, ganaplacide/lumefantrine in a recent Phase 3 trial offers hope for continued progress rolling back malaria even as resistance to artemisinin combination therapies (ACT) escalates. A next-generation antimalarial drug GanLum (ganaplacide/lumefantrine, KLU156) slightly outperformed a standard of care Artemisinin Combination Therapy (ACT) in a recent Phase 3 trial […] Continue reading -> Posts navigation Older posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy
WHO Issues First-Ever Guidelines for GLP-1 Drugs – Including Obesity 04/12/2025 Sophia Samantaroy First-ever WHO guidelines recommending the use of glucagon-like peptide-1 (GLP-1) therapies for the treatment of obesity in adults has been issued by the World Health Organization – in what the global health agency said is a “conditional” sign of approval for the cutting edge medications that have become widely popular. The new WHO recommendations go […] Continue reading -> European Commission Moves to Ease AI Rules as WHO Warns of Patient Risks due to Regulatory Vacuum 19/11/2025 Felix Sassmannshausen Technological advances in Artificial Intelligence applications for healthcare are quickly outpacing regulatory and ethical safeguards, creating a dangerous gap in patient safety, warns a milestone report on AI in Health Systems, published Wednesday by the World Health Organization’s European Region (WHO/EURO). Paradoxically, the WHO’s urgent call for tighter AI regulation coincided with a far-reaching European […] Continue reading -> New Malaria Drug Candidate Exceeds Cure Rate for Standard ACTs in Phase 3 Trial 12/11/2025 Felix Sassmannshausen The 97% cure rate for the novel compound, ganaplacide/lumefantrine in a recent Phase 3 trial offers hope for continued progress rolling back malaria even as resistance to artemisinin combination therapies (ACT) escalates. A next-generation antimalarial drug GanLum (ganaplacide/lumefantrine, KLU156) slightly outperformed a standard of care Artemisinin Combination Therapy (ACT) in a recent Phase 3 trial […] Continue reading -> Posts navigation Older posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy
European Commission Moves to Ease AI Rules as WHO Warns of Patient Risks due to Regulatory Vacuum 19/11/2025 Felix Sassmannshausen Technological advances in Artificial Intelligence applications for healthcare are quickly outpacing regulatory and ethical safeguards, creating a dangerous gap in patient safety, warns a milestone report on AI in Health Systems, published Wednesday by the World Health Organization’s European Region (WHO/EURO). Paradoxically, the WHO’s urgent call for tighter AI regulation coincided with a far-reaching European […] Continue reading -> New Malaria Drug Candidate Exceeds Cure Rate for Standard ACTs in Phase 3 Trial 12/11/2025 Felix Sassmannshausen The 97% cure rate for the novel compound, ganaplacide/lumefantrine in a recent Phase 3 trial offers hope for continued progress rolling back malaria even as resistance to artemisinin combination therapies (ACT) escalates. A next-generation antimalarial drug GanLum (ganaplacide/lumefantrine, KLU156) slightly outperformed a standard of care Artemisinin Combination Therapy (ACT) in a recent Phase 3 trial […] Continue reading -> Posts navigation Older posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy
New Malaria Drug Candidate Exceeds Cure Rate for Standard ACTs in Phase 3 Trial 12/11/2025 Felix Sassmannshausen The 97% cure rate for the novel compound, ganaplacide/lumefantrine in a recent Phase 3 trial offers hope for continued progress rolling back malaria even as resistance to artemisinin combination therapies (ACT) escalates. A next-generation antimalarial drug GanLum (ganaplacide/lumefantrine, KLU156) slightly outperformed a standard of care Artemisinin Combination Therapy (ACT) in a recent Phase 3 trial […] Continue reading -> Posts navigation Older posts